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THE ROCKEFELLER UNIVERSITY
Everyone who deals with the phenomena ofpathology
soon comes to know that nature often speaks her
secrets with a still, small voice out ofa dense
thicket ofhappenings.
-PEYTON

Rous, 1942

RESEARCH
PROFILES
FALL 1982

Oncogenes: Evolutionary Hitchhikers
Shortly after Peyton Rous, a young pathologist, began studying cancer at The Rockefeller Institute for Medical Research,
a chicken breeder brought to his laboratory a hen with a large
lump on one leg. The hen had a connective tissue tumor
called spindle-cell sarcoma, which in mammals, including
humans, is often highly malignant. Rous inoculated some
healchy chickens with this tissue and they developed sarcomas. He then inoculated other chickens with a filtrate of
cancerous material from which all cells, including the cancer
cells, had been removed. Those chickens, toO, developed
tumors. Rous concluded that a virus, too small to be seen with
the microscopes of the day, was the cause. But in 1911, the
idea of virus-induced cancer was received with considerable
scepticism. Rous was to experience what a colleague called a
"long, dark period of acknowledgment deferred."
In 1966, near the end of a protean career marked by many
honors and many other major contributions to medical
science, Peyton Rous was awarded the Nobel Prize "for his
discovery of tumor-inducing viruses." As Charles Huggins of
the University of Chicago and a co-recipient of the prize later
recollected: "A thousand Swedish medical students held a
formal dinner in Stockholm in honor of Dr. Rous.... One
remembers Peyton (age 87) very late in the evening standing
on his chair with glass in hand singing skoal with the young
students." Peyton Rous died on February 16, 1970.
0

Whether or not viruses are an important cause of cancer in
human beings remains- 70 years later-an unresolved question. But since the days ofRous's discovery, it has been found
that viruses cause various kinds of cancers in many animals,
from chickens co apes, and scientists like Professor Hidesaburo Hanafusa of The Rockefeller University are studying
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these animal viruses to learn more about basic cancer mechanisms. They have learned, among other things, about specific
genes, present in some viruses, that are involved in the malignant transformation of cells. This information has led
recently, and surprisingly, to the identification of what a
growing number of researchers believe may be potential
"cancer genes" present in all cells, including human cells, and
to a new theory of how cancer happens.
The so-called oncogene theory (onc meaning "mass" in
Greek) has gained great momentum. The result of the converging of different lines of research in many laboratories, it
represents years of dogged effon sparked by those leaps of
imagination and serendipitous adventures by which science
proceeds. The field of viral oncology has lately become, in
Dr. Hanafusa's words, "very busy and very lively." As Dr.
Michael Bishop of the University of California, San Francisco, wrote some months ago, "For the first time investigators have perceived the dim outlines of events that can induce
cancerous growth."
For Dr. Hanafusa, who is one of five scientists to receive a
1982 Albert Lasker Basic Medical Research Award this

November for contributions to the understanding of cancer
genes, the new findings dramatically confirm his perception,
25 years ago as a student in Japan, that tumor viruses are "a
very attractive biological problem." In the years since, he has
used his training as a biochemist, combined with new insights
and new technologies from molecular biology and genetics, to
observe, isolate, control, and explain the events that occur
and the elements that interact when virus meets cell.
In the viral oncology laboratory at Rockefeller, which he
established in 1973, Dr. Hanafusa and his group concentrate
on studies of viruses that induce tumors in birds, panicularly
Rous sarcoma virus (RSV), the prototype of animal tumor
viruses and still a favorite laboratory model. In 1979 they
reponed the results of a series of experiments that have lent
weight to the belief, to quote Michael Bishop (another 1982
Lasker-Award winner) again, that "a final common pathway
by which all tumors arise may be pan of the genetic dowry of
every living cell."
In the experiments, Dr. Hanafusa and his colleagues inoculated chickens with a preparation of Rous virus, which normally brings on sarcomas within abour a week. In this case,
however, the viruses used in the preparation were defective
mutants, lacking most of the particular DNA sequence
known to constitute the tumor-inducing gene called src for
sarcoma, within the viral gen,e bundle (genome). Not surprisingly, tumors did not appear in a week. Two months later,
tumors did arise, however, but very far from the site of inoculation. When the viruses in these tumors were analyzed, they
were found to contain complete src genes. To understand the
significance of that finding, which Dr. Hanafusa confesses
astonished him, and to understand its place in the oncogene
thesis, it is necessary to know something abour the course of
tumor virus research in general, and of Dr. Hanafusa's work
in panicular.

A TALE OF TWO VIRUSES
A virus consists of its genome and some proteins sealed in a
protein envelope. To survive and replicate, viruses must infil-
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trate and commandeer the metabolic machinery of cells. Dr.
Hanafusa's involvement with viruses began at Osaka University, where he earned his bachelor's and doctoral degrees.
Wanting to understand "how such miniature parasites with
such minimal genetic information could capture control of
complex, healthy organisms," he did some studies of the virus
of smallpox at the university's Research Institute for Microbial Diseases. His interest in viruses as cancer agents was reinforced by news from the United States that researchers there
had recently developed the means for growing tumor viruses
in tissue culture, making it possible to observe cell transformation in progress.
In 1961 he obtained a postdoctoral appointment at the
University of California at Berkeley, to work in the labora-

tory of Harry Rubin, one of the pioneers in tumor virus
research. (Accompanying Dr. Hanafusa across the ocean was
one of his colleagues from Osaka, also a new Ph.D., an
organic chemist named Teruko Inoue, who had become
Teruko Hanafusa three years earlier, and who is still her husband's closest research collaborator.) "Rubin was working
with Rous virus, which appealed to me," Dr. Hanafusa
explains, "because its action is direct, quick, and quantitative-ideal for biochemical study. With a good viral preparation, I soon found that I could get a transformation of cells
within 24 hours."
The newcomer's first assignment produced his first major
finding. "Rubin had noticed something that perplexed him.
He had found that all the Rous virus he isolated seemed to be
contaminated with another virus, which he called Rous-associated virus. A number of such associated viruses have since
been identified. He wanted me to see if I could isolate pure
Rous virus. In trying to do that, what we found was that the
Rous virus was defective. It could transform cells-make
them cancerous--=---- but it could not replicate itself. It needed
the other virus to help it do that, which is why it was not
found alone. The defect, we subsequently learned, was that it
could not make the envelope glycoproteins necessary for
entry into the cell.
"Defective viruses had I{een seen in bacteriophagesviruses that infect bacteria-but not in animal viruses. They
hadn't even been suspected. So our finding was rather shocking. What was even more surprising was that the Rous virus
being studied in Europe wasn't defective, even though all of
the viruses, here and abroad, had been cultured from ones
originally isolated by Rous himself. Whether they represent
different strains or evolved differently from the same strain is
still a question. The defective virus made an excellent tool for
study. By changing the helper virus we could begin to alter
properties and activities of the Rous virus." (The find also
made the young Dr. Hanafusa "jUSt a little famous" in the
relatively small world of viral oncology.)
In 1964 he went to Paris, as a visiting scientist at the College de France, and continued the line of investigation he had
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begun with Rubin. Two years later, he returned to the United
States to accept an appointment as chief of viral oncology at
the Public Health Research Institute in New York, where he
remained until coming to Rockefeller.

"BACKWARD" VIRUSES
In cells, genetic instructions are transcribed from strips of
DNA-deoxyribonucleic acid-into strips of RNA, another
nucleic acid. This messenger RNA, as it is called, then transmits the DNA's orders which specify primarily what protein
to assemble. Unlike cellular genes, which are always DNA,
viruses can be made of DNA or RNA. For a long time, the
mode of action of RN A viruses, such as Rous sarcoma virus,
mystified scientists because the accepted dogma was that
genetic instructions could flow only from DNA to RNA. But
it turned out that RNA viruses, now also called retroviruses,
work backward: their RNA is transcribed into virus DNA,
which then hooks into the cellular DNA.
The clue to solving the backward-virus mystery was found
independently in the laboratories of David Baltimore of MIT
(who earned his Ph.D. at Rockefeller) and Howard Temin of
the University of Wisconsin. They isolated an enzyme, appropriately named reverse transcriptase, that they demonstrated
to be the mechanism for transcribing viral RNA into provirus
DNA. Experimenting with a mutant strain of Rous sarcoma
virus deficient in reverse transcriptase, Dr. Hanafusa confirmed the enzyme's essential role in viral replication.
The discovery of reverse transcriptase was a giant step forward both conceptually and technically. "Until then," Dr.
Hanafusa points Out, "the analysis of viral-specific RNA in
cells infected with retrovirus was extremely difficult since
infected cells contain abundant amounts of cellular RNA.
Using reverse transcriptase, it became possible for us to synthesize DNA complementary to RNA of the viral genome
and to use the complementary DNA as a probe to detect the
viral RN A in the cell, with which it will link."
The finding, around the same time, of an RSV mutant

which is temperature-sensitive in its transforming ability but
not in its ability to replicate gave the first direct proof that a
viral gene was responsible for inducing transformation.
Because these mutants can be turned on and off by varying
the temperature to which they are exposed, they have
become invaluable aids in tumor research. The most widely
used of these mutants was isolated in Dr. Hanafusa's
laboratory.
"In the 1970s," says Dr. Hanafusa, "genetic analysis of
RNA tumor viruses came into full blossom." The genome of
Rous sarcoma virus was the first to be mapped. It turned out
to be very small, even for a virus, with only four genes: one
coding for structural proteins, one for reverse transcriptase,
one for the envelope proteins, and one-the sre gene-for

A duster 0/ cells transformed by Rous Jarcoma virus. The shape and re/racti!ity 0/
theJe transformed cel!J are very different
from the surrounding normal chicken cells.
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transformation. Dr. Hanafusa's experiments with mutant
viruses lacking src helped to establish its function. Other
genes were later pinpointed in a variety of cumor viruses that
infect different animal species.

THE GENETIC DOWRY
As stated earlier, viruses with transforming genes induce
cumors quickly and directly, in living animals as in tissue cul• cure. But there are other viruses, without cancer genes, that
also cause cumors, although less directly and more slowly.
And there are the cancers, including human cancers, that cannot be ascribed to viruses, that stem from chemical or other
carcinogens. How do their mechanisms relate? For a long
time it was thought that they did not. Then, some years ago,
researchers studying viral transforming genes began to notice
DNA sequences in uninfected cells that looked very much
like viral oncogenes.
"DNA sequences homologous to the RNA sequences of
the src gene in Rous virus were found in the chromosomes of
normal chickens and many other vertebrates," says Dr. Hanafusa. "This unexpected finding raised the possibility, which
later studies proved to be the case, that viral transforming

genes originated as cellular genes and were picked up long
ago by viruses, by means of nacural genetic recombination."
The cellular genes that became viral genes began, in effect, as
hitchhikers on the evolutionary road. Presumably, they
recombined with viral genes much as, in the experiment Dr.
Hanafusa reported in 1979, src-defective viruses recombined
with homologous sequences in the cells of the chickens he
infected. The significant point about Dr. Hanafusa's recombined src gene is not that it looked like a viral src but that it
behaved like one: it caused cumors.
Most researchers assume that oncogenes have persisted in
cells because they have a vital function in normal cell life: to
produce a protein the cell needs. They further speculate that
it may be only when that protein is overproduced that it
adversely affects other proteins, which in turn bring about
such changes as cellular distortion and unrestrained growth
characteristic of cancer. The protein for which the src gene
codes in chicken cells has been identified as kinase, an
enzyme that catalyses the addition of phosphate on other proteins. Dr. Hanafusa's recovered viruses, in which the src gene
had been put back together, produced this kinase. He has
found that the protein is also present in much smaller
amounts in normal chickens. How are these potential onco-
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A schematic drawing ofRous virus DNA
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genes in cells turned on? Provirus ON A contains sequences
at both ends that are thought to contain a triggering device.
These sequences are called LTR, for "long terminal repeats."
When a normally dormant cellular oncogene is captured by a
virus, the expression of the oncogene comes under the control of this trigger.
Avian leukosis virus is a virus without a specific cancer gene
but with LTR sequences. Adjunct Professor William
Hayward, now at Memorial Sloan-Kettering Cancer Center,
who has been a member of Dr. Hanafusa's laboratory for a
number of years, discovered that these leukosis virus LTR
sequences turned on a cellular gene, called myc, which is
homologous to a viral transforming gene. His studies showed
that, contrary to the cellular oncogene being captured by a
virus, in this case the leukosis virus' LTR is incorporated
within the chromosome in front of the cellular myc sequences.
In more recent studies in other laboratories, oncogenes,
homologous to viral transforming genes, have been isolated
from human bladder and colon cancers. "It seems," says Dr.
Hanafusa, "that LTR-like sequences, or promoters, are present in normal chromosomes but are not 'important,' from the
point of view of cancer, unless near an oncogene. Thus, we
can now speculate that either relocation of these sequences or
mutation of the cellular promoter can activate the cellular
oncogene and result in cancer."

TO UNDERSTAND CANCER
On the door of Dr. Hanafusa's office, there is a large lapel
pin, the kind given out by an airline company as souvenirs, a
gift from a student. Written on it, in Hawaiian, are the words,
''I'm the boss." In the laboratory, the "boss" looks barely
older than his graduate students. It is hard to imagine these
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young people being daunted by a man who enjoys relating
that when, in his own student days in Osaka, he was allowed
to use a brand new piece of expensive equipment (imported
from America and, coincidentally, designed at Rockefeller),
"I broke it!"
Dr. Hanafusa and his colleagues, principal among them Dr.
Teruko Hanafusa, who has been largely responsible for the
isolation and characterization of the mutant viruses through
which so much has been learned, and Dr. Lu Hai Wang, who
has made an enormous contribution by his analysis of viral
RNA and who is now actively working to elucidate the mechanisms of viral RNA processing, are governed by one objective: to understarrd cancer.
As Dr. Hanafusa stresses: "The new ideas are very exciting.
They look good, but the phenomenon of cell transformation
is incredibly complicated. We know that in Rous virus infection the sre gene action is a primary event, but whether we can
correlate that with the activity of cellular oncogenes remains
to be seen. Then there's the' question of how the gene product-the kinase protein-converts normal cells. We don't
have any real fix on how many changes occur in the course of
transformation. Those are the crucial questions, the tough
ones." Then he adds: "I have always believed that virus
research would prove applicable to all cancerous transformation. It seems to be the case. 1 hope."
0
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